Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2015
At a glance
- Drugs Alvespimycin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Kosan Biosciences
- 28 Oct 2008 Status changed from planning to discontinued, as reported by ClinicalTrials.gov.
- 23 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780000).
- 28 Feb 2008 Kosan have reported that this trial will not be continued.